goat anti cd45 antibody (R&D Systems)
Structured Review

Goat Anti Cd45 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 142 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/goat+anti+cd45/pmc12395052-60-16-19?v=R%26D+Systems
Average 96 stars, based on 142 article reviews
Images
1) Product Images from "Pharmacological inhibition of IL12β is effective in treating pressure overload-induced cardiac inflammation and heart failure"
Article Title: Pharmacological inhibition of IL12β is effective in treating pressure overload-induced cardiac inflammation and heart failure
Journal: Frontiers in Immunology
doi: 10.3389/fimmu.2025.1624940
Figure Legend Snippet: Pharmacological inhibition of IL12β attenuated TAC-induced LV inflammation. (A, B) Representative images and quantified data of LV CD45 + leukocytes performed by immuno-histological staining. (C) Flow cytometry plot for the identification of CD45 + leukocytes in the LV. (D) Quantified data of the number of CD45 + leukocytes per LV. (E) The percentage of immune cell subsets within CD45 + leukocytes. (F) Quantified data of number of different immune cell subsets per LV. *p<0.05; # p<0.05 IgG-treated TAC mice compared with the control; † p<0.05 anti-IL12β-treated TAC mice compared with IgG-treated TAC mice; Neutro, Neutrophils; Mφ, Macrophage; Mono, Monocytes; DCs, Dendritic Cells; NK, Natural Killer Cells; n = 3–5 mice per group.
Techniques Used: Inhibition, Staining, Flow Cytometry, Control
Figure Legend Snippet: Pharmacological inhibition of IL12β attenuated TAC-induced pulmonary inflammation. (A, B) Representative images and quantified data of infiltrated CD45 + leukocytes in the lung performed by immuno-histological staining. (C) The percentage of immune cell subsets within CD45 + leukocytes. (D) The percentage of different macrophage subsets within F4/80 macrophages. (E) The percentage of immune cell subsets within CD3 + T cells. *p<0.05; # p<0.05 IgG-treated TAC mice compared with the control; † p<0.05 anti-IL12β-treated TAC mice compared with IgG-treated TAC mice; $ p<0.05 anti-IL12β-treated TAC mice compared with the control; Mφ, Macrophage; DCs, Dendritic Cells; NK, Natural Killer Cells; AMφ, Alveolar Mφ; IMφ, Interstitial Mφ; MdMφ, Monocyte-derived Mφ; NKT, Natural Killer T Cells; n = 4–5 mice per group.
Techniques Used: Inhibition, Staining, Control, Derivative Assay
Figure Legend Snippet: Anti-IL12β antibody treatment attenuated TAC-induced pulmonary F4/80 + macrophage accumulation and activation. (A) Flow cytometry plots for F4/80 + macrophages. (B) Quantified data of the percentage of F4/80 + cells within CD45 + cells. (C) Flow cytometry plots for the detection of MHCII expression in F4/80 + cells. (D, E) Quantified data of the percentage of MHCII high F4/80 + cells within F4/80 + and CD45 + cells, respectively. (F) Quantified data of mean fluorescent intensity of MHCII in F4/80 + cells. (G) Representative histograms of MHCII expression in F4/80 + cells of the indicated groups. *p<0.05; n = 4–5 mice per group.
Techniques Used: Activation Assay, Flow Cytometry, Expressing
Figure Legend Snippet: Anti-IL12β antibody treatment attenuated TAC-induced alveolar macrophage accumulation and activation of alveolar and interstitial macrophages. (A) Flow cytometry plots of lung alveolar macrophages (AMφ). (B) Quantified data of the percentage of AMφ, Ly6C low interstitial macrophages (IMφ), and monocyte-derived Ly6C high interstitial macrophages (MdMφ) within CD45 + cells. (C) Flow cytometry plots for the identification of IMφ and MdMφ. (D) Quantified data of the percentage of MHCII high AMφ, MHCII high IMφ, and MHCII high MdMφ within CD45 + leukocytes. (E) Flow cytometry plots for the detection of MHCII expression in AMφ. (F) Quantified data of mean fluorescent intensity of MHCII in AMφ, IMφ, and MdMφ. (G-I) Quantified data of MHCII high AMφ, MHCII high IMφ, and MHCII high MdMφ within AMφ, IMφ, and MdMφ, respectively. (J) Representative histograms of MHCII expression in AMφ, IMφ, and MdMφ of the indicated groups. *p<0.05; # p<0.05 IgG-treated TAC mice compared with the control; † p<0.05 anti-IL12β-treated TAC mice compared with IgG-treated TAC mice; $ p<0.05 anti-IL12β-treated TAC mice compared with the control; MHCII high (MHCII + ); n = 4–5 mice per group.
Techniques Used: Activation Assay, Flow Cytometry, Derivative Assay, Expressing, Control
Figure Legend Snippet: Anti-IL12β antibody treatment attenuated TAC-induced activation of pulmonary dendritic cells (CD11c high F4/80 - ). (A) Flow cytometry plots of lung CD11c high F4/80 - cells. (B) Quantified data of the percentage of CD11c high F4/80 - cells within CD45 + cells. (C) Flow cytometry plots for the detection of MHCII expression in CD11c high F4/80 - cells. (D, E) Quantified data of the percentage of MHCII high CD11c high F4/80 - cells within CD11c high F4/80 - cells and CD45 + cells, respectively. (F) Quantified data of mean fluorescent intensity of MHCII in CD11c high F4/80 - cells. (G) Representative histograms of MHCII expression in CD11c high F4/80 - cells of the indicated groups. *p<0.05; n = 4–5 mice per group.
Techniques Used: Activation Assay, Flow Cytometry, Expressing

